The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...

Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.